End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
45,250 KRW | +0.33% | +10.10% | +1.69% |
Apr. 05 | Nomura Adjusts DukSan Neolux’s Price Target to KRW56,000 From KRW54,000, Keeps at Buy | MT |
2023 | Tranche Update on DukSan Neolux Co.,Ltd's Equity Buyback Plan announced on March 2, 2022. | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- The firm trades with high earnings multiples: 23.91 times its 2024 earnings per share.
- The company's enterprise value to sales, at 5315.83 times its current sales, is high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.69% | 804M | - | ||
+17.07% | 66.31B | A- | ||
-0.29% | 48.46B | A- | ||
+21.61% | 43.27B | B+ | ||
+26.72% | 27.41B | A- | ||
+9.25% | 19.26B | C+ | ||
-2.14% | 16.61B | B+ | ||
+9.75% | 16.58B | B+ | ||
-15.01% | 14.41B | C+ | ||
-30.22% | 14.02B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- A213420 Stock
- Ratings DukSan Neolux Co.,Ltd